These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23553710)

  • 1. Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of β-secretase: potential therapeutics for Alzheimer's disease.
    Schwörer R; Zubkova OV; Turnbull JE; Tyler PC
    Chemistry; 2013 May; 19(21):6817-23. PubMed ID: 23553710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-entity heparan sulfate glycomimetic clusters for therapeutic applications.
    Tyler PC; Guimond SE; Turnbull JE; Zubkova OV
    Angew Chem Int Ed Engl; 2015 Feb; 54(9):2718-23. PubMed ID: 25640820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel heparan sulphate analogues: inhibition of beta-secretase cleavage of amyloid precursor protein.
    Patey SJ; Yates EA; Turnbull JE
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1116-8. PubMed ID: 16246059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase.
    Scholefield Z; Yates EA; Wayne G; Amour A; McDowell W; Turnbull JE
    J Cell Biol; 2003 Oct; 163(1):97-107. PubMed ID: 14530380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low anticoagulant heparin oligosaccharides as inhibitors of BACE-1, the Alzheimer's β-secretase.
    Zhang X; Zhao X; Lang Y; Li Q; Liu X; Cai C; Hao J; Li G; Yu G
    Carbohydr Polym; 2016 Oct; 151():51-59. PubMed ID: 27474542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
    Yan R; Vassar R
    Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of heparan sulfate in the generation of Abeta.
    Patey SJ
    Drug News Perspect; 2006 Sep; 19(7):411-6. PubMed ID: 17080204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
    Patey SJ; Edwards EA; Yates EA; Turnbull JE
    Neurodegener Dis; 2008; 5(3-4):197-9. PubMed ID: 18322389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing Amyloid β Interactions with Synthetic Heparan Sulfate Oligosaccharides.
    Wang P; Zhao J; Hossaini Nasr S; Otieno SA; Zhang F; Qiang W; Linhardt RJ; Huang X
    ACS Chem Biol; 2021 Oct; 16(10):1894-1899. PubMed ID: 33592143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
    Kumar A; Roy S; Tripathi S; Sharma A
    J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
    Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
    J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concise chemoenzymatic synthesis of heparan sulfate analogues as potent BACE-1 inhibitors.
    Li J; Li J; Sun T; Cai C; Shao M; Yu G
    Carbohydr Polym; 2019 Aug; 217():232-239. PubMed ID: 31079681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.